Pramipexole (dihydrochloride)

Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D₂, D₃ and D₄ receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)^[1][2][3]. In Vitro: Pramipexole shows a low binding affinity for D1-type receptor, with an IC50 of >50,000 nM^[1].
Pramipexole dihydrochloride (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size^[3].
Pramipexole dihydrochloride attenuates levodopa-induced toxicity in mesencephalic cultures, suggests that pramipexole may be cytoprotective to dopamine neurons in tissue culture^[4].
In Vivo: Pramipexole dihydrochloride (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals^[5].
Pramipexole dihydrochloride improves neurological recovery^[5].
Pramipexole dihydrochloride prevents ischemic cell death via mitochondrial pathways in ischemic stroke^[5].